These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20920042

  • 41. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N, Montgomery IA, Moffett RC, Flatt PR.
    Biochem Pharmacol; 2013 Jan 01; 85(1):81-91. PubMed ID: 23085436
    [Abstract] [Full Text] [Related]

  • 42. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice.
    Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, Deng Y.
    J Alzheimers Dis; 2013 Jan 01; 37(3):623-35. PubMed ID: 24008687
    [Abstract] [Full Text] [Related]

  • 43. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
    Hamilton A, Patterson S, Porter D, Gault VA, Holscher C.
    J Neurosci Res; 2011 Apr 01; 89(4):481-9. PubMed ID: 21312223
    [Abstract] [Full Text] [Related]

  • 44. Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.
    Tamura K, Minami K, Kudo M, Iemoto K, Takahashi H, Seino S.
    PLoS One; 2015 Apr 01; 10(5):e0126003. PubMed ID: 25938469
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture.
    Toso C, McCall M, Emamaullee J, Merani S, Davis J, Edgar R, Pawlick R, Kin T, Knudsen LB, Shapiro AM.
    Transpl Int; 2010 Mar 01; 23(3):259-65. PubMed ID: 19821955
    [Abstract] [Full Text] [Related]

  • 50. GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment.
    Krass M, Volke A, Rünkorg K, Wegener G, Lund S, Abildgaard A, Vasar E, Volke V.
    Acta Neuropsychiatr; 2015 Feb 01; 27(1):25-32. PubMed ID: 25469828
    [Abstract] [Full Text] [Related]

  • 51. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
    Ellenbroek JH, Töns HA, Westerouen van Meeteren MJ, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F, de Koning EJ.
    Diabetologia; 2013 Sep 01; 56(9):1980-6. PubMed ID: 23771206
    [Abstract] [Full Text] [Related]

  • 52. Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance function of islet β cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice with high-fat diet-induced diabetes.
    Hao T, Zhang H, Li S, Tian H.
    Int J Mol Med; 2017 Apr 01; 39(4):1029-1036. PubMed ID: 28290604
    [Abstract] [Full Text] [Related]

  • 53. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.
    Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C.
    Eur J Endocrinol; 2013 May 01; 168(5):699-706. PubMed ID: 23392214
    [Abstract] [Full Text] [Related]

  • 54. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
    Pathak NM, Pathak V, Lynch AM, Irwin N, Gault VA, Flatt PR.
    Mol Cell Endocrinol; 2015 Sep 05; 412():95-103. PubMed ID: 26048772
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Liraglutide-induced acute pancreatitis.
    Jeyaraj S, Shetty AS, Kumar CR, Nanditha A, Krishnamoorthy S, Raghavan A, Raghavan K, Ramachandran A.
    J Assoc Physicians India; 2014 Jan 05; 62(1):64-6. PubMed ID: 25327099
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
    Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O'Shea D.
    J Eur Acad Dermatol Venereol; 2013 Nov 05; 27(11):1440-3. PubMed ID: 22691169
    [Abstract] [Full Text] [Related]

  • 60. Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
    Tanday N, Lafferty RA, Flatt PR, Irwin N.
    Diabetes Obes Metab; 2022 Dec 05; 24(12):2353-2363. PubMed ID: 35848461
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.